Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117168 · ClinicalTrials.gov registry record
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
A clinical trial of Leukemia and Sarcoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- 57,816
- Enrollment target
- 1
- Study location
NCT01117168: Active study of Leukemia and Sarcoma, sponsored by Children's Oncology Group.
NCT01117168 is a study of Leukemia and Sarcoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 57,816 participants, above the 239-participant average among 233 other Leukemia trials with a reported enrollment target (24091% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01117168, a study of Leukemia and Sarcoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- 57,816 participants
- Enrollment target
- 1
- Study location
Study Summary
The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.
Conditions Studied
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57,816 participants |
| Start Date | 2010-04-30 |
| Est. Completion | 2030-12-31 |
What the registry record for NCT01117168 still lists
NCT01117168 is an observational study that tracks outcomes without assigning an intervention. Its 57,816 participants enrollment target places it among the larger protocols in the corpus, above the 239-participant average among 233 other Leukemia trials with a reported enrollment target (24091% higher).
The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT01117168 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01117168 about?
NCT01117168 is a clinical study titled "Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group". The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood ...
What is the current status of trial NCT01117168?
This trial is currently active not recruiting. The enrollment target is 57,816 participants. The study started on 2010-04-30. Estimated completion is 2030-12-31.
What conditions does trial NCT01117168 study?
This clinical trial studies the following conditions: Leukemia, Sarcoma, Pediatric Cancer, Brain Tumors.
Who is sponsoring clinical trial NCT01117168?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01117168 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01117168's enrollment target sits among peer trials
57,816 1st of 233 higher than 233 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00785525 · 60,000 participants · Phase 3
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
- NCT01825499 · 60,000 participants
Vermont Oxford Network Very Low Birth Weight Database
- NCT02850588 · 60,000 participants
SVS VQI TransCarotid Revascularization Surveillance Project
- NCT03752840 · 60,200 participants · NA
Village-Integrated Eye Worker Trial II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI